A new study found that chronic kidney disease (CKD) patients who received IV contrast-enhanced imaging faced no more risk of developing contrast-induced nephropathy than those who did not receive contrast material. Matt O'Connor | Diagnostic Imaging | Health Imaging

Gadolinium-based contrast agents (GBCAs) are typically administered during follow-up imaging of multiple sclerosis (MS) patients. Michael Walter | Care Delivery | Radiology Business

Increased signal intensities in different brain regions presumably caused by linear and macrocyclic gadolinium-based contrast agents (GBCAs) could be an indication that gadolinium accumulation is more widespread than previously thought, according to a study presented on Wednesday at RSNA 2018. By Wayne Forrest, AuntMinnie.com staff writer

New findings are coming out on almost a weekly basis about trace elements of gadolinium left in human tissue after scans with MRI contrast agents. What do we know about this phenomenon, and how serious is it? We talk to Dr. Robert McDonald, PhD, of the Mayo Clinic in Rochester, MN.